ARC TALKS
WEBINAR SERIES

AL Amyloidosis Clinical Trials

November 4 I 12pm - 1pm




Kristen Hsu

Executive Director of Research
Amyloidosis Research Consortium

About ARC

Amyloidosis Research Consortium

ARC's mission is to improve and extend the lives of those with amyloidosis



ARC Talks Supported By

Amyloidosis Research Consortium





















Before We Begin



This webinar is recorded. We will post the webinar on our website so you can view it again later.



Submit your questions anytime via the Q&A box. We will try to answer them at the end.



If you are having trouble with the audio using your computer, you can dial in (check your email for info).

AL Amyloidosis Booklets



arci.org/booklets

ARC TALKS
WEBINAR SERIES

AL Amyloidosis Clinical Trials

November 4 I 12pm - 1pm




Kristen Hsu

Executive Director of Research
Amyloidosis Research Consortium


If you are here to learn about ATTR clinical trials…

…check out our July webinar focusing on ATTR amyloidosis clinical trials on our website or YouTube channel.
Our next ATTR amyloidosis clinical trials webinar is planned for Jan 2027

https://arci.org/resources-category/webinars/




https://www.youtube.com/@Amyloidosis_ARC




AL Amyloidosis Clinical trials

Investigative approaches to treating AL Amyloidosis....



…are like treating a clogged bathtub



Slow down or even stop the production of amyloid (turning off the faucet)

Remove existing amyloid (unclog the tub)

Ideal scenario would be turning off the faucet and unclogging the tub

Investigative Approaches to Treat AL Amyloidosis

Anti-plasma cell therapies


- Monoclonal antibodies
  - Daratumumab (DARZALEX)
  - Isatuximab (SARCLISA)
  - Elotuzumab (EMPLICITI)
  - Belantamab mafodotin (BLENREP)
- BCL-2 Inhibitors
  - Venetoclax (VENCLEXTA)
- Bispecific/Trispecific
  - Teclistamab (TECVAYLI)
  - Ramantamig (JNJ-79635322)
  - Linvoseltamab (LYNOZYFIC)
  - Etentamig (ABBV-383)
  - Elranatamab (ELREXFIO)
- Cellular Therapies
  - AZD0120
  - NXC-201
  - AUTO8

Light chain Stabilizers

- PROT-001 (lambda)

Anti-Fibril Agents

- Anselamimab (CAEL-101)
- NI009 (lambda)
- AT-02



Red = investigational for AL amyloidosis

Treatments by light chain type and disease status

			Light chain type: Lambda vs kappa	Disease Status: Newly Diagnosed	Disease Status: Relapsed/Refractory
Monoclonal Antibodies	Janssen	Daratumumab (Darzalex)		Approved	
	Sanofi	Isatuximab		Clinical trial active not recruiting	Clinical trial status unknown
	BMS	Elotuzumab			Clinical trial status unknown
	GSK	Belantamab mafodotin		Clinical trial recruiting (n=60)	
Bispecific/ Trispecific Antibodies	Janssen	Teclistamab		Clinical trial recruiting (n=25)	
		Ramantamig (JNJ-79635322)		Clinical trial recruiting (n=15)	Clinical trial ongoing
	Regeneron	Linvoseltamab		Phase 3 Planned (n=382)	Clinical trial recruiting
	AbbVie	Etentamig (ABBV-383)		Phase 3 Planned (n=370)	Clinical trial recruiting
	Pfizer	Elranatamab		Phase 2 Planned (n=64)	Clinical trial recruiting
Cellular Therapies	Nexcella	NXC-201		Phase 3 Planned (n=260)	Clinical trial ongoing
	Alexion/AZ	AZD0120			Clinical trial recruiting
	Autolus	AUTO8			Clinical trial recruiting
BCL2 Inhibitors	AbbVie	Venetoclax			Clinical trials ongoing
LC Stabilizer	Protego	PROT-001	Lambda	Phase 2/3 Planned (n=tba)	
Anti-Fibril Agents	Alexion/AZ	Anselamimab (CAEL-101)	Kappa	P3 benefit seen; recommended for approval in Japan	
		NI009	Lambda	Clinical trial planned; disease status unknown	
	Attralus	AT-02 (renal AL)			Clinical trial results 2H 2026

Treatments by light chain type and disease status

			Light chain type: Lambda vs kappa	Disease Status: Newly Diagnosed	Disease Status: Relapsed/Refractory
Monoclonal Antibodies	Janssen	Daratumumab (Darzalex)		Approved	
	Sanofi	Isatuximab		Clinical trial active not recruiting	Clinical trial status unknown
	BMS	Elotuzumab			Clinical trial status unknown
	GSK	Belantamab mafodotin		Clinical trial recruiting (n=60)	
Bispecific/ Trispecific Antibodies	Janssen	Teclistamab		Clinical trial recruiting (n=25)	
		Ramantamig (JNJ-79635322)		Clinical trial recruiting (n=15)	Clinical trial ongoing
	Regeneron	Linvoseltamab		Phase 3 Planned (n=382)	Clinical trial recruiting
	AbbVie	Etentamig (ABBV-383)		Phase 3 Planned (n=370)	Clinical trial recruiting
	Pfizer	Elranatamab		Phase 2 Planned (n=64)	Clinical trial recruiting
Cellular Therapies	Nexcella	NXC-201		Phase 3 Planned (n=260)	Clinical trial ongoing
	Alexion/AZ	AZD0120			Clinical trial recruiting
	Autolus	AUTO8			Clinical trial recruiting
BCL2 Inhibitors	AbbVie	Venetoclax			Clinical trials ongoing
LC Stabilizer	Protego	PROT-001	Lambda	Phase 2/3 Planned (n=tba)	
Anti-Fibril Agents	Alexion/AZ	Anselamimab (CAEL-101)	Kappa	P3 benefit seen; recommended for approval in Japan	
		NI009	Lambda	Clinical trial planned; disease status unknown	
	Attralus	AT-02 (renal AL)			Clinical trial results 2H 2026


ALANIS (Belantamab Mafodotin; antibody-drug conjugate)

Newly diagnosed AL amyloidosis

Recruiting Now

ClinicalTrials.gov ID	NCT07224672
Study Phase	Phase 2
Purpose of the study	Evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in newly diagnosed AL
Primary endpoint	**Complete hematologic response**: percentage of patients whose blood and urine tests no longer show the abnormal light chain
Key eligibility criteria	• Newly diagnosed, no prior treatments for AL amyloidosis • Not planning a stem cell transplant as first treatment • Mayo Stage I, II, or IIIa
Number of patients	60
Study Drug	Belantamab mafodotin (1 of 2 possible doses, given as an IV infusion) and CyBorD
Chance of receiving study drug?	All patients will receive study drug
How long?	Up to 2 years

Recruiting ALANIS Countries (as of 04Nov2026)



Recruiting ALANIS Centers(as of 04Nov2026)



Recruiting Centers:

- **California-** Los Angeles
- **Colorado-** Aurora
- **Connecticut-** New Haven
- **Massachusetts-** Boston
- **Minnesota-** Rochester
- **New Jersy-** Hackensack
- **Tennessee**- Nashville
- **Utah**- Salt Lake City

Treatments by light chain type and disease status

			Light chain type: Lambda vs kappa	Disease Status: Newly Diagnosed	Disease Status: Relapsed/Refractory
Monoclonal Antibodies	Janssen	Daratumumab (Darzalex)		Approved	
	Sanofi	Isatuximab		Clinical trial active not recruiting	Clinical trial status unknown
	BMS	Elotuzumab			Clinical trial status unknown
	GSK	Belantamab mafodotin		Clinical trial recruiting (n=60)	
Bispecific/ Trispecific Antibodies	Janssen	Teclistamab		Clinical trial recruiting (n=25)	
		Ramantamig (JNJ-79635322)		Clinical trial recruiting (n=15)	Clinical trial ongoing
	Regeneron	Linvoseltamab		Phase 3 Planned (n=382)	Clinical trial recruiting
	AbbVie	Etentamig (ABBV-383)		Phase 3 Planned (n=370)	Clinical trial recruiting
	Pfizer	Elranatamab		Phase 2 Planned (n=64)	Clinical trial recruiting
Cellular Therapies	Nexcella	NXC-201		Phase 3 Planned (n=260)	Clinical trial ongoing
	Alexion/AZ	AZD0120			Clinical trial recruiting
	Autolus	AUTO8			Clinical trial recruiting
BCL2 Inhibitors	AbbVie	Venetoclax			Clinical trials ongoing
LC Stabilizer	Protego	PROT-001	Lambda	Phase 2/3 Planned (n=tba)	
Anti-Fibril Agents	Alexion/AZ	Anselamimab (CAEL-101)	Kappa	P3 benefit seen; recommended for approval in Japan	
		NI009	Lambda	Clinical trial planned; disease status unknown	
	Attralus	AT-02 (renal AL)			Clinical trial results 2H 2026

IMPACT-AL (Teclistamab; BCMA-CD3 bispecific antibody)


Newly diagnosed AL amyloidosis

Recruiting Now

Amyloidosis Research Consortium

ClinicalTrials.gov ID	NCT07110844
Study Phase	Phase 2
Purpose of the study	Assess the effectiveness and safety of teclistamab-daratumumab combination; evaluate whether this combination is able to effectively decrease the level light chains, avoiding organ damage, improving organ function, and prolonging life
Primary endpoint	**Complete hematologic response**: percentage of patients whose blood and urine tests no longer show the abnormal light chain
Key eligibility criteria	• Newly diagnosed, with no prior treatment for AL amyloidosis • At least 1 organ affected (e.g., heart or kidneys) • Measurable disease (dFLC ≥ 50 mg/L or M-protein ≥ 5 g/L) • Patients with NT-proBNP above 8,500 or on dialysis are excluded
Number of patients	25
Study Drug	Teclistamab and Daratumumab (given as subcutaneous (under the skin) injections) - Teclistimab: Step up dosing for 1st week, weekly dosing until Month 1, then monthly dosing through Month 6 - Daratumumab: Weekly for 1st 2 months, then biweekly (every 2 weeks) through Month 6
Chance of receiving study drug?	All patients will receive study drug
How long?	6 months

Recruiting IMPACT-AL Centers (as of 04Nov2026)



Recruiting Centers:

- **Massachusetts-** Boston*
- **New York-** New York
- **Wisconsin**- Milwaukee

- *not yet recruiting

Treatments by light chain type and disease status

			Light chain type: Lambda vs kappa	Disease Status: Newly Diagnosed	Disease Status: Relapsed/Refractory
Monoclonal Antibodies	Janssen	Daratumumab (Darzalex)		Approved	
	Sanofi	Isatuximab		Clinical trial active not recruiting	Clinical trial status unknown
	BMS	Elotuzumab			Clinical trial status unknown
	GSK	Belantamab mafodotin		Clinical trial recruiting (n=60)	
Bispecific/ Trispecific Antibodies	Janssen	Teclistamab		Clinical trial recruiting (n=25)	
		Ramantamig (JNJ-79635322)		Clinical trial recruiting (n=15)	Clinical trial ongoing
	Regeneron	Linvoseltamab		Phase 3 Planned (n=382)	Clinical trial recruiting
	AbbVie	Etentamig (ABBV-383)		Phase 3 Planned (n=370)	Clinical trial recruiting
	Pfizer	Elranatamab		Phase 2 Planned (n=64)	Clinical trial recruiting
Cellular Therapies	Nexcella	NXC-201		Phase 3 Planned (n=260)	Clinical trial ongoing
	Alexion/AZ	AZD0120			Clinical trial recruiting
	Autolus	AUTO8			Clinical trial recruiting
BCL2 Inhibitors	AbbVie	Venetoclax			Clinical trials ongoing
LC Stabilizer	Protego	PROT-001	Lambda	Phase 2/3 Planned (n=tba)	
Anti-Fibril Agents	Alexion/AZ	Anselamimab (CAEL-101)	Kappa	P3 benefit seen; recommended for approval in Japan	
		NI009	Lambda	Clinical trial planned; disease status unknown	
	Attralus	AT-02 (renal AL)			Clinical trial results 2H 2026

RAMANTAMIG study (JNJ-79635322; BCMA-GPRC5D-CD3 trispecific antibody)


Newly diagnosed AL amyloidosis

Recruiting Now

Amyloidosis Research Consortium

ClinicalTrials.gov ID	NCT06768489
Study Phase	Phase 1b
Purpose of the study	Part 1 (dose escalation): identify the recommended phase 2 dose and schedule(s) to be safe for Ramantamig in combination with daratumumab Part 2 (dose expansion): characterize the safety and tolerability of Ramantamig at the selected doses and in disease subgroups
Primary endpoint	**Safety**: how often side effects occur and how serious they are, including dose-limiting side effects and abnormal lab results
Key eligibility criteria (AL amyloidosis)	• Newly diagnosed, with no prior treatment for AL amyloidosis or multiple myeloma • Able to do most daily activities independently • No symptomatic multiple myeloma • No severe swallowing difficulty from an enlarged tongue • No serious heart, lung, or other specified medical conditions
Number of patients	15 AL amyloidosis patients (261 multiple myeloma and high-risk smoldering multiple myeloma)
Study Drug	Ramantamig, given as given as subcutaneous (under the skin) injections, and daratmumumab
Chance of receiving study drug?	All patients will receive study drug
How long?	Up to 3 Years 3 months

Recruiting Ramantamig Countries (as of 04Nov2026)



Treatments by light chain type and disease status

			Light chain type: Lambda vs kappa	Disease Status: Newly Diagnosed	Disease Status: Relapsed/Refractory
Monoclonal Antibodies	Janssen	Daratumumab (Darzalex)		Approved	
	Sanofi	Isatuximab		Clinical trial active not recruiting	Clinical trial status unknown
	BMS	Elotuzumab			Clinical trial status unknown
	GSK	Belantamab mafodotin		Clinical trial recruiting (n=60)	
Bispecific/ Trispecific Antibodies	Janssen	Teclistamab		Clinical trial recruiting (n=25)	
		Ramantamig (JNJ-79635322)		Clinical trial recruiting (n=15)	Clinical trial ongoing
	Regeneron	Linvoseltamab		Phase 3 Planned (n=382)	Clinical trial recruiting
	AbbVie	Etentamig (ABBV-383)		Phase 3 Planned (n=370)	Clinical trial recruiting
	Pfizer	Elranatamab		Phase 2 Planned (n=64)	Clinical trial recruiting
Cellular Therapies	Nexcella	NXC-201		Phase 3 Planned (n=260)	Clinical trial ongoing
	Alexion/AZ	AZD0120			Clinical trial recruiting
	Autolus	AUTO8			Clinical trial recruiting
BCL2 Inhibitors	AbbVie	Venetoclax			Clinical trials ongoing
LC Stabilizer	Protego	PROT-001	Lambda	Phase 2/3 Planned (n=tba)	
Anti-Fibril Agents	Alexion/AZ	Anselamimab (CAEL-101)	Kappa	P3 benefit seen; recommended for approval in Japan	
		NI009	Lambda	Clinical trial planned; disease status unknown	
	Attralus	AT-02 (renal AL)			Clinical trial results 2H 2026

LINKER-AL1 (linvoseltamab; BCMA-CD3 bispecific antibody)

Newly Diagnosed AL amyloidosis

Starting December 2026

Amyloidosis Research Consortium

ClinicalTrials.gov ID	NCT07901725
Study Phase	Phase 3
Purpose of the study	Evaluate if the safety and efficacy of linvoseltamab alone can deliver better disease control and outcomes than Dara-CyBodD
Primary endpoint	• **Part 1 – Safety**: how often side effects occur and how serious they are • **Part 2 – Complete hematologic response**: percentage of patients whose blood and urine tests no longer show the abnormal light chain
Key eligibility criteria	- No prior treatment for AL amyloidosis (diagnosis confirmed) - Measurable disease - Able to take care of yourself and up and about more than half the day - Adequate blood counts, kidney function, and liver function - No serious heart conditions, including significantly reduced heart function - No advanced multiple myeloma
Number of patients	382
Study Drug	Linvoseltamab
Chance of receiving study drug?	Participants will be randomly assigned to receive either linvoseltamab or Dara-CyBorD
How long?	Up to 7 years

LINKER-AL2 (linvoseltamab; BCMA-CD3 bispecific antibody)


Relapsed/refractory AL amyloidosis

Recruiting Now

Amyloidosis Research Consortium

ClinicalTrials.gov ID	NCT06292780
Study Phase	Phase 1/2
Purpose of the study	- Phase 1: Evaluate the safety of linvoseltamab and determine recommended Phase 2 dose - Phase 2: Evaluate the safety and efficacy of linvoseltamab
Primary endpoint	• **Phase 1 – Dose finding**: percentage of patients with side effects serious enough to stop the dose from being increased in the first 28 days • **Phase 2 – Complete hematologic response**: percentage of patients whose blood and urine tests no longer show the abnormal light chain
Key eligibility criteria	• At least 1 prior treatment, and still needs further treatment • Measurable disease (dFLC) • NT-proBNP ≤ 8,500 ng/L (limits how much the heart can be affected)
Number of patients	220
Study Drug	linvoseltamab
Chance of receiving study drug?	All patients will receive study drug
How long?	~3 years
Website	https://clinicaltrials.regeneron.com/clinical-trials/a0MPr0000008ANBMA2/nct06292780

Recruiting LINKER-AL2 Countries (as of 04Nov2026)



Recruiting LINKER-AL2 Centers (as of 04ANov2026)



Recruiting Centers:

- **California-** Duarte
- **Colorado**- Denver
- **Massachusetts**-Boston
- **Michigan**- Detroit
- **New York-** Buffalo
- **Ohio-** Columbus
- **Texas**- Houston
- **Tennessee**- Nashville

Treatments by light chain type and disease status

			Light chain type: Lambda vs kappa	Disease Status: Newly Diagnosed	Disease Status: Relapsed/Refractory
Monoclonal Antibodies	Janssen	Daratumumab (Darzalex)		Approved	
	Sanofi	Isatuximab		Clinical trial active not recruiting	Clinical trial status unknown
	BMS	Elotuzumab			Clinical trial status unknown
	GSK	Belantamab mafodotin		Clinical trial recruiting (n=60)	
Bispecific/ Trispecific Antibodies	Janssen	Teclistamab		Clinical trial recruiting (n=25)	
		Ramantamig (JNJ-79635322)		Clinical trial recruiting (n=15)	Clinical trial ongoing
	Regeneron	Linvoseltamab		Phase 3 Planned (n=382)	Clinical trial recruiting
	AbbVie	Etentamig (ABBV-383)		Phase 3 Planned (n=370)	Clinical trial recruiting
	Pfizer	Elranatamab		Phase 2 Planned (n=64)	Clinical trial recruiting
Cellular Therapies	Nexcella	NXC-201		Phase 3 Planned (n=260)	Clinical trial ongoing
	Alexion/AZ	AZD0120			Clinical trial recruiting
	Autolus	AUTO8			Clinical trial recruiting
BCL2 Inhibitors	AbbVie	Venetoclax			Clinical trials ongoing
LC Stabilizer	Protego	PROT-001	Lambda	Phase 2/3 Planned (n=tba)	
Anti-Fibril Agents	Alexion/AZ	Anselamimab (CAEL-101)	Kappa	P3 benefit seen; recommended for approval in Japan	
		NI009	Lambda	Clinical trial planned; disease status unknown	
	Attralus	AT-02 (renal AL)			Clinical trial results 2H 2026

ETENTAMIG (ABBV-383;BCMA-CD3 bispecific antibody)

Newly Diagnosed AL amyloidosis

Starting November 2026

Amyloidosis Research Consortium

ClinicalTrials.gov ID	NCT07793422
Study Phase	Phase 3
Purpose of the study	Evaluate the efficacy and safety of Etentamig compared with Dara-CyBorD in the treatment of newly diagnosed AL amyloidosis.
Primary endpoint	• **Safety**: how often side effects occur and how serious they are • **Complete hematologic response**: percentage of patients whose blood and urine tests no longer show the abnormal light chain • **Major organ deterioration progression-free survival**: how long patients live without the disease worsening or serious heart or kidney complications
Key eligibility criteria	• Newly diagnosed, with no prior treatment for AL amyloidosis • At least 1 organ affected (e.g., heart or kidneys) • Measurable disease • Mayo stage I, II, or IIIa (stage IIIb may qualify for the randomized portion) • Able to take care of yourself and up and about more than half the day
Number of patients	370
Study Drug	Etentamig (injections)
Chance of receiving study drug?	Safety run-in, all participants receive etentamig. In the Randomized Portion, participants will be randomly assigned to receive either etentamig or Dara-CyBorD
How long?	Up to 5 years

ETENTAMIG (ABBV-383;BCMA-CD3 bispecific antibody)


Relapsed/refractory AL amyloidosis

Recruiting Now

Amyloidosis Research Consortium

Clinicaltrials.gov ID	NCT06158854
Study Phase	Phase 1/2
Purpose of the study	Safety evaluation and preliminary activity
Primary endpoint	• **Dose finding**: dose-limiting side effects and the recommended dose • **Dose expansion**: early signs of how well etentamig works
Key eligibility criteria	• At least 1 prior treatment, including a proteasome inhibitor (e.g., bortezomib) and an anti-CD38 antibody (e.g., daratumumab) • At least 1 organ affected, now or in the past • Measurable disease (dFLC ≥ 50 mg/L) • No multiple myeloma, plasma cell leukemia, Waldenström's macroglobulinemia, or non-AL amyloidosis
Number of patients	Approximately 76 patients
Study Drug	Infusions of etentamig every 4 weeks
Chance of receiving study drug?	All patients will receive study drug
How long?	Up to 2 years

Recruiting Etentamig Countries (as of 04ANov2026)



Recruiting Etentamig Centers (as of 04Nov2026)



Recruiting Centers:

- **Florida-** Miami
- **Massachusetts-** Boston
- **Minnesota-** Rochester
- **New York-** New York (3 centers)
- **North Carolina-** Charlotte, Winston-Salem
- **Oregon**- Portland
- **Tennessee-** Nashville
- **Washington-** Seattle
- **Wisconsin**-Milwaukee

Treatments by light chain type and disease status

			Light chain type: Lambda vs kappa	Disease Status: Newly Diagnosed	Disease Status: Relapsed/Refractory
Monoclonal Antibodies	Janssen	Daratumumab (Darzalex)		Approved	
	Sanofi	Isatuximab		Clinical trial active not recruiting	Clinical trial status unknown
	BMS	Elotuzumab			Clinical trial status unknown
	GSK	Belantamab mafodotin		Clinical trial recruiting (n=60)	
Bispecific/ Trispecific Antibodies	Janssen	Teclistamab		Clinical trial recruiting (n=25)	
		Ramantamig (JNJ-79635322)		Clinical trial recruiting (n=15)	Clinical trial ongoing
	Regeneron	Linvoseltamab		Phase 3 Planned (n=382)	Clinical trial recruiting
	AbbVie	Etentamig (ABBV-383)		Phase 3 Planned (n=370)	Clinical trial recruiting
	Pfizer	Elranatamab		Phase 2 Planned (n=64)	Clinical trial recruiting
Cellular Therapies	Nexcella	NXC-201		Phase 3 Planned (n=260)	Clinical trial ongoing
	Alexion/AZ	AZD0120			Clinical trial recruiting
	Autolus	AUTO8			Clinical trial recruiting
BCL2 Inhibitors	AbbVie	Venetoclax			Clinical trials ongoing
LC Stabilizer	Protego	PROT-001	Lambda	Phase 2/3 Planned (n=tba)	
Anti-Fibril Agents	Alexion/AZ	Anselamimab (CAEL-101)	Kappa	P3 benefit seen; recommended for approval in Japan	
		NI009	Lambda	Clinical trial planned; disease status unknown	
	Attralus	AT-02 (renal AL)			Clinical trial results 2H 2026

ELRANATAMAB; (BCMAxCD3 Bispecific Antibody)

Newly diagnosedAL amyloidosis

Starting soon

Amyloidosis Research Consortium

ClinicalTrials.gov ID	NCT07524634
Study Phase	Phase 2
Purpose of the study	Evaluate whether elranatamab can produce deep remissions and organ recovery in people with newly diagnosed AL amyloidosis, and compare two different dosing schedules.
Primary endpoint	**Complete hematologic response**: percentage of patients whose blood and urine tests no longer show the abnormal light chain at the end of treatment
Key eligibility criteria	• Newly diagnosed, with no prior treatment for AL amyloidosis (confirmed by biopsy) • Not Mayo stage IIIb (most advanced heart involvement) • Able to take care of yourself and up and about more than half the day • No active multiple myeloma • No serious or uncontrolled heart conditions
Number of patients	64
Study Drug	Elranatamab; administered by SC injection
Chance of receiving study drug?	All patients will receive Elranatamab
How long?	6 months of active treatment, followed by follow-up visits for up to 2 years (with an option to extend to 5 years)

ELRANATAMAB; (BCMAxCD3 Bispecific Antibody)

Relapsed/refractory AL amyloidosis

Recruiting Now

Amyloidosis Research Consortium

ClinicalTrials.gov ID	NCT06569147
Study Phase	Phase 1/2
Purpose of the study	Evaluate the safety, tolerability, and effectiveness of Elranatamab in patients with relapsed or refractory AL amyloidosis
Primary endpoint	• **Phase 1 – Dose finding**: the recommended Phase 2 dose • **Phase 2 – Overall hematologic response**: percentage of patients whose abnormal light chain levels improve meaningfully (partial response or better)
Key eligibility criteria	• At least 1 prior treatment (at least 2 cycles), with disease that has relapsed or is refractory • Evidence that light chain levels are rising • Adequate organ and bone marrow function • No prior BCMA-targeted CAR-T or bispecific antibody
Number of patients	49 (estimated to enrollment)
Study Drug	Elranatamab; administered by SC injection
Chance of receiving study drug?	All patients will receive Elranatamab
How long?	6 28 day cycles; follow up Q3 months for 2.5 years

Recruiting Elranatamab Centers (as of 04Nov2026)



Recruiting Centers:

- **Connecticut-** New Haven
- **Massachusetts** Boston (x3)
- **Ohio**- Cleveland

Treatments by light chain type and disease status

			Light chain type: Lambda vs kappa	Disease Status: Newly Diagnosed	Disease Status: Relapsed/Refractory
Monoclonal Antibodies	Janssen	Daratumumab (Darzalex)		Approved	
	Sanofi	Isatuximab		Clinical trial active not recruiting	Clinical trial status unknown
	BMS	Elotuzumab			Clinical trial status unknown
	GSK	Belantamab mafodotin		Clinical trial recruiting (n=60)	
Bispecific/ Trispecific Antibodies	Janssen	Teclistamab		Clinical trial recruiting (n=25)	
		Ramantamig (JNJ-79635322)		Clinical trial recruiting (n=15)	Clinical trial ongoing
	Regeneron	Linvoseltamab		Phase 3 Planned (n=382)	Clinical trial recruiting
	AbbVie	Etentamig (ABBV-383)		Phase 3 Planned (n=370)	Clinical trial recruiting
	Pfizer	Elranatamab		Phase 2 Planned (n=64)	Clinical trial recruiting
Cellular Therapies	Nexcella	NXC-201		**Phase 3 Planned (n=260)**	**Clinical trial ongoing**
	Alexion/AZ	AZD0120			Clinical trial recruiting
	Autolus	AUTO8			Clinical trial recruiting
BCL2 Inhibitors	AbbVie	Venetoclax			Clinical trials ongoing
LC Stabilizer	Protego	PROT-001	Lambda	Phase 2/3 Planned (n=tba)	
Anti-Fibril Agents	Alexion/AZ	Anselamimab (CAEL-101)	Kappa	P3 benefit seen; recommended for approval in Japan	
		NI009	Lambda	Clinical trial planned; disease status unknown	
	Attralus	AT-02 (renal AL)			Clinical trial results 2H 2026

NEXICART-3 (NXC-201; BCMA CAR-T cell therapy)

Newly diagnosed AL amyloidosis

Starting January 2027

Amyloidosis Research Consortium

ClinicalTrials.gov ID	NCT07709715
Study Phase	Phase 3
Purpose of the study	Evaluate the efficacy and safety of NXC-201 compared with Dara-CyBorD in the treatment of newly diagnosed AL amyloidosis.
Primary endpoints	• **Complete hematologic response**: percentage of patients whose blood and urine tests no longer show the abnormal light chain • **Major organ deterioration progression-free survival**: how long patients live without the disease worsening or serious heart or kidney complications
Key eligibility criteria	• Newly diagnosed, with no prior treatment for AL amyloidosis or multiple myeloma • At least 1 organ affected (e.g., heart or kidneys) • Not Mayo stage IIIb (most advanced heart involvement) • Able to take care of yourself and up and about more than half the day • No multiple myeloma • No other cancer in the past 3 years, and no stroke or seizure in the past 6 months
Number of patients	260
Study Drug	NXC-201; Single infusion following leukopharesis and lymphodepletion
Chances of receiving study drug?	Participants will be randomly assigned to receive either NXC-201 or Dara-CyBorD
How long?	5 years

Treatments by light chain type and disease status

			Light chain type: Lambda vs kappa	Disease Status: Newly Diagnosed	Disease Status: Relapsed/Refractory
Monoclonal Antibodies	Janssen	Daratumumab (Darzalex)		Approved	
	Sanofi	Isatuximab		Clinical trial active not recruiting	Clinical trial status unknown
	BMS	Elotuzumab			Clinical trial status unknown
	GSK	Belantamab mafodotin		Clinical trial recruiting (n=60)	
Bispecific/ Trispecific Antibodies	Janssen	Teclistamab		Clinical trial recruiting (n=25)	
		Ramantamig (JNJ-79635322)		Clinical trial recruiting (n=15)	Clinical trial ongoing
	Regeneron	Linvoseltamab		Phase 3 Planned (n=382)	Clinical trial recruiting
	AbbVie	Etentamig (ABBV-383)		Phase 3 Planned (n=370)	Clinical trial recruiting
	Pfizer	Elranatamab		Phase 2 Planned (n=64)	Clinical trial recruiting
Cellular Therapies	Nexcella	NXC-201		Phase 3 Planned (n=260)	Clinical trial ongoing
	Alexion/AZ	AZD0120			Clinical trial recruiting
	Autolus	AUTO8			Clinical trial recruiting
BCL2 Inhibitors	AbbVie	Venetoclax			Clinical trials ongoing
LC Stabilizer	Protego	PROT-001	Lambda	Phase 2/3 Planned (n=tba)	
Anti-Fibril Agents	Alexion/AZ	Anselamimab (CAEL-101)	Kappa	P3 benefit seen; recommended for approval in Japan	
		NI009	Lambda	Clinical trial planned; disease status unknown	
	Attralus	AT-02 (renal AL)			Clinical trial results 2H 2026

ALACRITY (AZD0120; CD19/BCMA CAR-T cell therapy)


Relapsed/refractory AL amyloidosis

Recruiting Now

Amyloidosis Research Consortium

ClinicalTrials.gov ID	NCT07081646
Study Phase	Phase 1b/2
Purpose of the study	Evaluate the Safety and Tolerability of AZD0120
Primary endpoint	• **Phase 1b – Safety**: how often side effects occur and how serious they are • **Phase 2 – Complete hematologic response**: percentage of patients whose blood and urine tests no longer show the abnormal light chain
Key eligibility criteria	• At least 1 prior treatment, and still needs further treatment • At least 1 organ affected, now or in the past • Measurable disease (dFLC > 20 mg/L or M-protein > 5 g/L) • Able to do most daily activities independently (ECOG 0–2) • No prior CAR-T or BCMA-targeted therapy, and no bispecific or trispecific antibody in the past 6 months
Number of patients	91
Study Drug	AZD0120; Single infusion following leukopharesis and lymphodepletion
Chance of receiving study drug?	All patients will receive AZD0120
How long?	Minimum of 6 months

Recruiting ALACRITY Countries (as of 04Nov2026)



Recruiting ALACRITY Centers (as of 04Nov2026)



Recruiting Centers:

- **Arizona-** Phoenix
- **California**- San Francisco
- **Florida-** Tampa
- **Massachusetts-** Boston
- **Michigan-** Detroit
- **Minnesota-** Rochester
- **Missouri-** St. Louis
- **New York-** New York (x3)
- **Ohio-** Cleveland
- **Tennessee**- Nashville

Treatments by light chain type and disease status

			Light chain type: Lambda vs kappa	Disease Status: Newly Diagnosed	Disease Status: Relapsed/Refractory
Monoclonal Antibodies	Janssen	Daratumumab (Darzalex)		Approved	
	Sanofi	Isatuximab		Clinical trial active not recruiting	Clinical trial status unknown
	BMS	Elotuzumab			Clinical trial status unknown
	GSK	Belantamab mafodotin		Clinical trial recruiting (n=60)	
Bispecific/ Trispecific Antibodies	Janssen	Teclistamab		Clinical trial recruiting (n=25)	
		Ramantamig (JNJ-79635322)		Clinical trial recruiting (n=15)	Clinical trial ongoing
	Regeneron	Linvoseltamab		Phase 3 Planned (n=382)	Clinical trial recruiting
	AbbVie	Etentamig (ABBV-383)		Phase 3 Planned (n=370)	Clinical trial recruiting
	Pfizer	Elranatamab		Phase 2 Planned (n=64)	Clinical trial recruiting
Cellular Therapies	Nexcella	NXC-201		Phase 3 Planned (n=260)	Clinical trial ongoing
	Alexion/AZ	AZD0120			Clinical trial recruiting
	Autolus	AUTO8			Clinical trial recruiting
BCL2 Inhibitors	AbbVie	Venetoclax			Clinical trials ongoing
LC Stabilizer	Protego	PROT-001	Lambda	Phase 2/3 Planned (n=tba)	
Anti-Fibril Agents	Alexion/AZ	Anselamimab (CAEL-101)	Kappa	P3 benefit seen; recommended for approval in Japan	
		NI009	Lambda	Clinical trial planned; disease status unknown	
	Attralus	AT-02 (renal AL)			Clinical trial results 2H 2026

SHIELD-AL (PROT-001; lambda stabilizer)

Newly diagnosed AL amyloidosis

Planned for 1Q 2027

Amyloidosis Research Consortium

ClinicalTrials.gov ID	Not yet posted
Study Phase	Phase 2/3 (Part A: safety and dose confirmation; Part B: pivitol study to test whether it works)
Purpose of the study	Evaluate whether adding PROT-001 to standard treatment leads to faster, deeper organ responses and fewer heart complications
Key eligibility criteria	• Newly diagnosed AL amyloidosis • Lambda light chain type only
Number of patients	To be announced (global study)
Study Drug	PROT-001, an oral pill, taken alongside standard treatment
Chance of receiving study drug?	Randomly assigned to PROT-001 or placebo, both added to standard treatment. Neither patients nor doctors know which (double-blind).
How long?	To be announced

First-in-class: the first oral oral pill designed to stabilize lambda light chains so they don't misfold into amyloid. Details will be posted on ClinicalTrials.gov, and will be added to MAP when the study opens.

Treatments by light chain type and disease status

			Light chain type: Lambda vs kappa	Disease Status: Newly Diagnosed	Disease Status: Relapsed/Refractory
Monoclonal Antibodies	Janssen	Daratumumab (Darzalex)		Approved	
	Sanofi	Isatuximab		Clinical trial active not recruiting	Clinical trial status unknown
	BMS	Elotuzumab			Clinical trial status unknown
	GSK	Belantamab mafodotin		Clinical trial recruiting (n=60)	
Bispecific/ Trispecific Antibodies	Janssen	Teclistamab		Clinical trial recruiting (n=25)	
		Ramantamig (JNJ-79635322)		Clinical trial recruiting (n=15)	Clinical trial ongoing
	Regeneron	Linvoseltamab		Phase 3 Planned (n=382)	Clinical trial recruiting
	AbbVie	Etentamig (ABBV-383)		Phase 3 Planned (n=370)	Clinical trial recruiting
	Pfizer	Elranatamab		Phase 2 Planned (n=64)	Clinical trial recruiting
Cellular Therapies	Nexcella	NXC-201		Phase 3 Planned (n=260)	Clinical trial ongoing
	Alexion/AZ	AZD0120			Clinical trial recruiting
	Autolus	AUTO8			Clinical trial recruiting
BCL2 Inhibitors	AbbVie	Venetoclax			Clinical trials ongoing
LC Stabilizer	Protego	PROT-001	Lambda	Phase 2/3 Planned (n=tba)	
Anti-Fibril Agents	Alexion/AZ	Anselamimab (CAEL-101)	Kappa	P3 benefit seen; Recommended for approval in Japan	
		NI009	Lambda	Clinical trial planned; disease status unknown	
	Attralus	AT-02 (renal AL)			Clinical trial results 2H 2026

CARES (anselamimab (CAEL-101); anti-fibril antibody)

Newly Diagnosed AL amyloidosis

Amyloidosis Research Consortium

Study Phase	Phase 3
Purpose of the study	Determine whether anselamimab improves overall survival, reduces cardiovascular related hospitalizations and it is safe and well tolerated in patients with stage IIIa or stage IIIb AL amyloidosis.
Primary endpoint	• **Overall survival**: how long patients live • **Cardiovascular hospitalization**: how often patients are hospitalized for heart problems
Key eligibility criteria	• Advanced AL amyloidosis with heart involvement • Mayo stage IIIa (NT-proBNP 650–8,500 ng/L, elevated troponin) or stage IIIb (NT-proBNP > 8,500 ng/L) at screening • Planned standard treatment with a CyBorD-based regimen
Number of patients	281 stage IIIa; 125 stage IIIb
Study Drug	Anselamimab combined with SoC plasma cell dyscrasia;intravenous (into a vein) infusions
Chance of receiving study drug?	2/3 (66.7%) received anselamimab and standard of care 1/3 (33.3%) received placebo and standard of care
How long?	At least 18 months

AT-02 (anti-fibril depleter)
AL amyloidosis with kidney disease

Study Phase	Phase 2
Purpose of the study	Evaluate the Long-term Safety and Tolerability of AT-02
Primary endpoint	**Safety**: how often side effects occur and how serious they are, including changes in lab results
Key eligibility criteria	• Prior treatment directed at plasma cells, with a very good partial response (VGPR) or complete response (CR); daratumumab maintenance allowed • At least 6 months since that response • Kidneys still affected: reduced kidney function (eGFR 20–75 mL/min/1.73m²) and/or urine protein that hasn't dropped by at least 25% in the past year or since response
Number of patients	15
Study Drug	AT-02, given as an IV infusion once every 2 weeks, for up to 24 weeks (6 months)
Chance of receiving study drug?	All patients will receive study drug
How long?	At least 6 months

Treatments by light chain type and disease status

			Light chain type: Lambda vs kappa	Disease Status: Newly Diagnosed	Disease Status: Relapsed/Refractory
Monoclonal Antibodies	Janssen	Daratumumab (Darzalex)		Approved	
	Sanofi	Isatuximab		Clinical trial ongoing	Clinical trial status unknown
	BMS	Elotuzumab			Clinical trial status unknown
	GSK	Belantamab mafodotin		Clinical trial recruiting (n=60)	
Bispecific/ Trispecific Antibodies	Janssen	Teclistamab		Clinical trial recruiting (n=25)	
		Ramantamig (JNJ-79635322)		Clinical trial recruiting (n=15)	Clinical trial ongoing
	Regeneron	Linvoseltamab		Phase 3 Planned (n=382)	Clinical trial recruiting
	AbbVie	Etentamig (ABBV-383)		Phase 3 Planned (n=370)	Clinical trial recruiting
	Pfizer	Elranatamab		Phase 2 Planned (n=64)	Clinical trial recruiting
Cellular Therapies	Nexcella	NXC-201		Phase 3 Planned (n=260)	Clinical trial ongoing
	Alexion/AZ	AZD0120			Clinical trial recruiting
	Autolus	AUTO8			Clinical trial recruiting
BCL2 Inhibitors	AbbVie	Venetoclax			Clinical trials ongoing
LC Stabilizer	Protego	PROT-001	Lambda	Phase 2/3 Planned (n=tba)	
Anti-Fibril Agents	Alexion/AZ	Anselamimab (CAEL-101)	Kappa	P3 benefit seen; recommended for approval in Japan	
		NI009	Lambda	Clinical trial planned; disease status unknown	
	Attralus	AT-02 (renal AL)			Clinical trial results 2H 2026

Newly diagnosed? Ask about trials first

8

trials for newly diagnosed AL amyloidosis

3 recruiting now, 5 opening Nov 2026 – early 2027

1,176+

patients needed to fill them

Not counting SHIELD-AL (size not yet announced)

3

Phase 3 trials testing a new drug head-to-head

against today's standard, Dara-CyBorD

To the physicians watching

1 Raise trials at diagnosis. Nearly all of these studies require no prior treatment, so the window closes at the first dose.

2 Refer early and often. Most open at specialized centers. MAP and the study teams can help find the nearest site.


3 Make it routine. Every eligible patient who hears about a trial helps these studies finish on time.

AL amyloidosis is rare. These trials can only succeed if eligible patients are referred.

How to find clinical trials

- You can find and stay informed of clinical trials a few different ways:
  - Clinicaltrials.gov
  - Talk to your healthcare provider
  - Follow patient organizations like ARC, ASG, country specific groups, etc.
  - Sign up for My Amyloidosis Pathfinder (MAP)

Amyloidosis Research Consortium



Discover Personalized Treatment Centers & Clinical Trials for Your Amyloidosis

myamyloidosispathfinder.org

map

POWERED BY

PATIENT DISCOVERY®